Welcome to our dedicated page for Xcelerate news (Ticker: XCRT), a resource for investors and traders seeking the latest updates and insights on Xcelerate stock.
Xcelerate Inc. (XCRT) is a diversified healthcare innovator operating across virtual health technology, consumer skincare solutions, and medical equipment licensing. This page provides investors and industry professionals with authoritative updates on the company’s latest developments, strategic partnerships, and regulatory milestones.
Access real-time announcements covering earnings reports, product launches, intellectual property updates, and market expansion initiatives. Our curated news collection ensures you stay informed about XCRT’s advancements in telemedicine platforms, clinically tested skincare formulations like Ceramedx®, and patented surgical technologies.
Bookmark this page for streamlined access to press releases, SEC filings, and analysis of Xcelerate’s cross-sector growth strategies. Regular updates provide insights into how the company integrates engineering innovations with healthcare solutions while maintaining rigorous compliance standards.
Xcelerate, Inc. (OTC PINK:XCRT) announced the acquisition of a patent portfolio from HS Pharmaceuticals LLC, enhancing its focus on dermatological products for chronic wounds and infections. The deal includes four issued and one pending U.S. patents, as well as two issued and one pending European patent, totaling millions in developmental costs. The acquisition involves issuing 10 million shares of restricted common stock and establishing a profit-sharing arrangement. This move aims to strengthen Xcelerate's technology base and aligns with its strategy to acquire cutting-edge medical innovations.
Xcelerate, Inc. (OTC Markets: XCRT) announced the engagement of SmallCapVoice.com, an investor relations firm, to enhance communication with shareholders. CEO Michael O'Shea highlighted the importance of this partnership in increasing corporate exposure and sharing developments at Xcelerate. The recent pilot program launch in Africa via its subsidiary, AfiyaSasa Africa, was noted as a significant milestone. SmallCapVoice.com aims to support Xcelerate's mission as a socially responsible global entity.
Xcelerate, Inc. (OTC Pink: XCRT) has initiated a pilot program in partnership with AfiyaSasa Africa, LLC to enhance healthcare delivery in Tanzania using AI and augmented reality. The company's 51% stake in ASA aims to address the shortage of medical professionals identified by Dr. Dilan Ellegala, who highlighted there were merely two neurosurgeons for 44 million people in the region. This innovative approach seeks to leverage advanced technology to improve medical services. More details can be found in the interview conducted by SmallCapVoice.com.
Xcelerate, Inc. (OTC Markets:XCRT) has signed a Membership Interest Purchase Agreement to acquire a 51% interest in AfiyaSasa Africa, LLC, a medical technology and virtual health start-up founded by Dr. Dilan Ellegala and Doyle Word. Additionally, Xcelerate has obtained patent pending status for its invention, 'Surgical Tools with Targeting Guidance', aimed at enhancing surgical procedures through improved tool handling and precision. This represents the beginning of a series of planned patents as Xcelerate advances its mission of integrating engineering with clinical care.
Xcelerate, Inc. (OTCMarkets: XCRT) announced the appointment of Thomas E. Mannle, Jr. to its Advisory Board, effective immediately. Thomas, a retired Lieutenant Colonel from the U.S. Army Reserve, brings over 25 years of consulting experience in healthcare and defense. His expertise includes planning, budgeting, and technology integration in organizations. Xcelerate's CEO, Michael O'Shea, stated that Thomas would provide invaluable guidance on advancing their project alliance with AfiyaSasa Africa and the development of patentable med-tech. The company expressed gratitude to its partners and investors for their support.
Xcelerate, Inc. (OTC PINK:XCRT) has acquired majority control of AfiyaSasa Africa, LLC, which focuses on medical technology for developing countries. A pilot program will launch in Tanzania across four hospitals, potentially expanding to a fifth location. The program aims to establish operational beta sites by Q2 2022 and generate revenue by the end of 2022. CEO Michael O'Shea highlighted the team's rapid progress and plans to up-list to the QB market to attract more investors.
On March 10, 2022, Xcelerate (OTC Pink: XCRT) CEO Michael O’Shea discussed the company's innovative use of artificial intelligence (AI) to enhance healthcare access in remote areas of Tanzania. The AI-driven software, initially designed for self-driving cars, allows patients to connect with healthcare professionals via mobile devices, improving treatment efficiency. Xcelerate aims to launch a beta site by Q2 2022 and anticipates generating revenue by year-end. Additionally, the company plans to file several patents related to its technology, aiming for an uplisting to OTCQB.
Xcelerate, Inc. (OTC Pink: XCRT) has acquired a 51% stake in AfiyaSasa Africa, LLC to improve healthcare access in Africa. CEO Michael O’Shea announced that Dr. Dilan Elegalla has moved to Tanzania to lead a pilot program, with Sriyanjit Perera as CEO of ASA. The initiative aims to utilize patented telemedicine technology to connect patients with physicians via mobile devices. With 650 million mobile users in Africa, ASA expects to launch a fully operational beta site by the end of Q2 2022 and become revenue-producing before year-end.
Xcelerate (OTC Pink: XCRT) has announced the appointment of Fran White to its Advisory Board, effective immediately. With over 40 years of experience, White founded MDC Associates, a consulting firm in regulatory affairs for the medical device and biotechnology sectors. Her expertise is expected to enhance Xcelerate's upcoming patent filings and support their business expansion in Africa through AfiyaSasa Africa, LLC. CEO Michael O’Shea highlighted her invaluable skills in recognizing market opportunities, particularly in developing regions.
Xcelerate (OTC Pink: XCRT) announced on January 25, 2022, that it filed a Supplemental Report with OTC Markets to remove its 'shell' status. CEO Michael O’Shea stated that following their recent Form 1-A filing with the SEC, the company believes it no longer qualifies as a shell under SEC rules. This change is a step toward Xcelerate's goal of uplisting to the OTCQB and ultimately to a national exchange.
FAQ
What is the current stock price of Xcelerate (XCRT)?
What is the market cap of Xcelerate (XCRT)?
